LUXE honors design team with cover story featuring project inspired by the majestic Teton landscape, iconic modern architecture and a stunning blue-chip art collection
JACKSON...
Multiple Closings and Residents Already Living at Harvest
WOODINVILLE, Wash., June 13, 2025 /PRNewswire/ -- The long-awaited dream of walking from your new home at Harvest...
New hub enhances rapid prototyping and boosts production to meet increased demand for custom flavor solutions
IRON RIDGE, Wis., June 12, 2025 /PRNewswire/ -- PS Seasoning...
ATLANTA, June 12, 2025 /PRNewswire/ -- Cox Enterprises proudly recognizes the exceptional efforts of its employees leading the way in carbon reduction and environmental...
TORONTO, June 12, 2025 /CNW/ - IsoEnergy Ltd. ("IsoEnergy" or the "Company") (NYSE: ISOU) (TSX: ISO) is pleased to announce the commencement of its summer...
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.
Alvotech (NASDAQ: ALVO, ALVO-SDB) tilkynnti í dag að fyrirtækið afhent bréf til þátttakenda í lokuðu hlutafjárútboði sem fram fór þann 4. júní sl. Um 40 stofnanafjárfestar tóku þátt í útboðinu. Um 60% af heildareftirspurninni kom frá fjárfestum í Svíþjóð, Noregi og Bretlandi, um 30% frá sjóðum í Bandaríkjunum og um 10% frá Íslandi. Yfir 80% bréfanna voru keypt af fjárfestum sem eru nýir hluthafar í Alvotech.
Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30% from US-based funds. Over 80% of the shares and Swedish Depositary Receipts (SDRs) allocated in the placement, were sold to investors that were not previously shareholders in Alvotech.
Total helps put FirstEnergy on pace to exceed 2025 tree donation goal
HOLMDEL, N.J., June 11, 2025 /PRNewswire/ -- Employee volunteers from Jersey Central Power...